Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

The Dapsone Conundrum: Understanding Implications of Adverse Reactions to Dapsone Including Dapsone Hypersensitivity Syndrome in Leprosy Patients Treated With Multidrug Therapy

Dev A, Narang T, Thakur V, et al. Wiley. International Journal of Dermatology. 2025;
Download PDF
Publication

Unprecedented in vivo activity of telacebec against Mycobacterium leprae

Chauffour A, Cambau E, Pethe K, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2025; 19 (5) : 1-11.
Download PDF
Publication

Identification of HLA-B*13:01 allele in leprosy patients with dapsone hypersensitivity syndrome in Ambon, Indonesia

Menaldi SLSW, Priyanto MH, Widaty S, et al. Frontiers Media SA. Frontiers in Tropical Diseases. 2025;
Download PDF
Publication

Efficacy of Multidrug Therapy (MDT) and exclusion of transplacental transmission in a pregnant woman with multibacillary leprosy

Argentina F, Bernolian N, Sakina M, et al. Lepra. Leprosy Review. 2025; 96 (2) : 1-5.
Download PDF
Publication

Ocular and Periocular Leprosy Confirmed by Polymerase Chain Reaction and Histopathology with Therapeutic Insights

Shambu SK, Nagaraj K, Ramesh S, et al. Informa UK Limited. Ocular Immunology and Inflammation. 2025;
Download PDF
Publication

Lepromatous Leprosy: A Rare and Unusual Presentation in the Post - Elimination Era

Mishra S, Madhual S. Indian J Lepr. 2025;
Download PDF
Publication

Challenges associated with dapsone for leprosy treatment in Indonesia - urgent need for access to alternative antimicrobial drugs

Krismawati H, Harianja M, Oktavian A, et al. Elsevier BV. The Lancet Regional Health - Southeast Asia. 2025;
Download PDF
Publication

Necrotic erythema nodosum leprosum – A case of severe lepromatous reaction in a multibacillary leprosy patient

Nagarajan HDP, Kamaraj B, Selvanathan K, et al. Elsevier BV. IDCases. 2025;
Download PDF
Publication

Efeitos adversos no tratamento da hanseníase: uma revisão sistemática

Espanhol HA, Hamada JPCB, Antonio GLN, et al. Brazilian Journals. Brazilian Journal of Health Review. 2025; 8 (1) : 14.
Download PDF
Publication

Challenges of the public health response to a rare case of non-autochthonous Mycobacterium leprae, Ireland, 2024

Marshall R, Horgan E, Duane H, et al. European Centre for Disease Control and Prevention (ECDC). Eurosurveillance. 2025;
Download PDF

Pagination

  • Page 1
  • Next page ››
Subscribe to Multi-drug therapy (MDT)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

  • infontd

© 2025 InfoNTD